Updated on 29 October 2014
Ebola opens its death account in Mali, West Africa
Singapore: The US Food and Drug Administration (FDA) has granted emergency authorization to two new Ebola diagnostic tests devised by BioFire, a BioMerieux subsidiary. The company has also announced that the health governing body had issued a fast-track designation for its FilmArray Ebola test.
The FilmArray BioThreat-E is the first commercial Ebola test to be authorized for use on patients with symptoms of the disease.The authorization is granted only when there is unavailability of suitable, approved alternatives and when unapproved medical drugs show a potential to fight or diagnose critical diseases.
BioFire's diagnostic tests are designed to detect infection in one hour and can be performed in hospitals that have the BioFire lab equipment. The company said in a statement that many hospitals in the US were already having BioFire equipment in their premises.
Global Ebola cases have crossed the 10,000 mark, and many health agencies have sounded alarm bells over the ravaging epidemic. The affected countries, Guinea and Sierra Leone have registered 400 cases in a couple of days.
Prominent vaccine makers have jumped into action to solve the crisis and WHO has assured that a million doses of Ebola vaccine will be ready by the end of 2015. As experts are brainstorming over newer methods of prevention and cure, Ebola multiplies to another country, opening its death account in Mali, West Africa.